s-adenosylmethionine has been researched along with bezafibrate in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barve, S; Bradford, BU; Chawla, RK; Colell, A; Deaciuc, I; Enomoto, N; Fernandez-Checa, JC; Garcia-Ruiz, C; Hill, D; Hirose, M; Ikejima, K; Ishii, H; Ishikawa, M; Joshi-Barve, S; Kaplowitz, N; Kitamura, T; Konno, A; Kono, H; Lin, M; McClain, CJ; Motomura, K; Nakamura, Y; Nelson, W; Ohata, M; Oide, H; Okamura, Y; Peter, S; Rivera, CA; Sato, N; Schmidt, J; Shimizu, H; Takei, Y; Thurman, R; Tsukamoto, H; Watson, W; Yamashina, S; Yokoyama, H | 1 |
| Alberto, JM; Gkikopoulou, E; Guéant, JL; Marguerite, V; Merten, M | 1 |
| Aubey, F; Bastin, J; Djouadi, F; Schlemmer, D | 1 |
| Aubey, F; Bastin, J; Djouadi, F; Ruiter, JP; Schlemmer, D; Strauss, AW; Wanders, RJ | 1 |
| Fukuda, S; Hasegawa, Y; Kobayashi, H; Li, H; Mushimoto, Y; Purevsuren, J; Yamaguchi, S | 1 |
| Fukao, T; Fukuda, S; Furui, M; Hasegawa, Y; Kobayashi, H; Li, H; Mushimoto, Y; Purevsuren, J; Takahashi, T; Taketani, T; Yamada, K; Yamaguchi, S | 1 |
| Ando, S; Arai, S; Asaka, I; Higaki, Y; Hitomi, H; Kaneoka, H; Kurose, Y; Nakashima, H; Osafune, K; Saito, T; Sakurai, H; Sudo, M; Tanaka, A; Yamada, K; Yamaguchi, S; Yasuno, T | 1 |
| Fukuda, T; Hiroki, M; Ishii, A; Shigematsu, Y; Shioya, A; Sugie, H; Takuma, H; Tamaoka, A; Yamaguchi, S | 1 |
| Aoyama, Y; Densupsoontorn, N; Fukao, T; Jirapinyo, P; Sathienkijkanchai, A; Vatanavicharn, N; Wasant, P; Yamada, K; Yamaguchi, S | 1 |
| Bo, R; Fukuda, S; Hasegawa, Y; Kobayashi, H; Mushimoto, Y; Purevsuren, J; Takahashi, T; Taketani, T; Yamada, K; Yamaguchi, S | 1 |
1 review(s) available for s-adenosylmethionine and bezafibrate
| Article | Year |
|---|---|
How is the liver primed or sensitized for alcoholic liver disease?
Topics: Animals; Bezafibrate; Endotoxins; Gene Expression; Hepatocytes; Humans; Hypolipidemic Agents; Iron; Kupffer Cells; Liver; Liver Diseases, Alcoholic; Mitochondria, Liver; Peroxisome Proliferators; S-Adenosylmethionine; Superoxides; Tretinoin; Tumor Necrosis Factor-alpha | 2001 |
9 other study(ies) available for s-adenosylmethionine and bezafibrate
| Article | Year |
|---|---|
Phospholipase D activation mediates cobalamin-induced downregulation of Multidrug Resistance-1 gene and increase in sensitivity to vinblastine in HepG2 cells.
Topics: 1-Butanol; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bezafibrate; Down-Regulation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Activators; Gene Expression; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Oleic Acid; Phosphatidylcholines; Phosphatidylethanolamine N-Methyltransferase; Phospholipase D; S-Adenosylmethionine; Vinblastine; Vitamin B 12 | 2013 |
Peroxisome proliferator activated receptor delta (PPARdelta) agonist but not PPARalpha corrects carnitine palmitoyl transferase 2 deficiency in human muscle cells.
Topics: Adult; Bezafibrate; Butyrates; Carnitine; Carnitine O-Palmitoyltransferase; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme Activation; Gene Expression; Humans; Hypolipidemic Agents; Muscle Fibers, Skeletal; Palmitic Acid; Phenylurea Compounds; Point Mutation; PPAR gamma; Thiazoles; Tritium | 2005 |
Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders.
Topics: Acyl-CoA Dehydrogenase, Long-Chain; Bezafibrate; Blotting, Western; Carnitine; DNA Primers; Dose-Response Relationship, Drug; Fibroblasts; Gene Expression Regulation, Enzymologic; Humans; Lipid Metabolism, Inborn Errors; Mitochondria; Mutation, Missense; Palmitates; Peroxisome Proliferator-Activated Receptors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2005 |
Effect of heat stress and bezafibrate on mitochondrial beta-oxidation: comparison between cultured cells from normal and mitochondrial fatty acid oxidation disorder children using in vitro probe acylcarnitine profiling assay.
Topics: Acyl-CoA Dehydrogenase; Acyl-CoA Dehydrogenase, Long-Chain; Bezafibrate; Carnitine; Cells, Cultured; Child; Fatty Acids; Fibroblasts; Hot Temperature; Humans; Hypolipidemic Agents; Lipid Metabolism, Inborn Errors; Mitochondria; Mitochondrial Diseases; Oxidation-Reduction; Stress, Physiological | 2010 |
Bezafibrate can be a new treatment option for mitochondrial fatty acid oxidation disorders: evaluation by in vitro probe acylcarnitine assay.
Topics: Bezafibrate; Carboxylic Acids; Carnitine; Cells, Cultured; Fatty Acids; Fibroblasts; Humans; Mitochondrial Diseases; Oxidation-Reduction | 2012 |
Functional analysis of iPSC-derived myocytes from a patient with carnitine palmitoyltransferase II deficiency.
Topics: Bezafibrate; Carnitine; Carnitine O-Palmitoyltransferase; Cell Differentiation; Cells, Cultured; Fibroblasts; Gene Expression Regulation; Humans; Male; Metabolism, Inborn Errors; Muscle Cells; Palmitoylcarnitine; Pluripotent Stem Cells; Young Adult | 2014 |
Amelioration of acylcarnitine profile using bezafibrate and riboflavin in a case of adult-onset glutaric acidemia type 2 with novel mutations of the electron transfer flavoprotein dehydrogenase (ETFDH) gene.
Topics: Adult; Bezafibrate; Carnitine; Drug Therapy, Combination; Electron-Transferring Flavoproteins; Humans; Hypolipidemic Agents; Iron-Sulfur Proteins; Multiple Acyl Coenzyme A Dehydrogenase Deficiency; Mutation; Oxidoreductases Acting on CH-NH Group Donors; Riboflavin; Treatment Outcome | 2014 |
Carnitine-acylcarnitine translocase deficiency: Two neonatal cases with common splicing mutation and in vitro bezafibrate response.
Topics: Bezafibrate; Carnitine; Carnitine Acyltransferases; Cells, Cultured; Child, Preschool; Fatal Outcome; Female; Fibroblasts; Genes, Lethal; Humans; Hypolipidemic Agents; In Vitro Techniques; Infant; Infant, Newborn; Lipid Metabolism, Inborn Errors; Male; Membrane Transport Proteins; Mitochondrial Diseases; Mutation; Treatment Outcome | 2015 |
Efficacy of bezafibrate on fibroblasts of glutaric acidemia type II patients evaluated using an in vitro probe acylcarnitine assay.
Topics: Adolescent; Adult; Age of Onset; Bezafibrate; Carnitine; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Enzyme Activators; Female; Fibroblasts; Humans; Infant; Infant, Newborn; Lipid Regulating Agents; Male; Multiple Acyl Coenzyme A Dehydrogenase Deficiency; Palmitoylcarnitine; Peroxisome Proliferator-Activated Receptors; Skin | 2017 |